Miguel Gonzalez-Barcia
Overview
Explore the profile of Miguel Gonzalez-Barcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varela-Rey I, Bandin-Vilar E, Toja-Camba F, Canizo-Outeirino A, Cajade-Pascual F, Ortega-Hortas M, et al.
Antibiotics (Basel)
. 2025 Jan;
13(12).
PMID: 39766593
The use of artificial intelligence (AI) and, in particular, machine learning (ML) techniques is growing rapidly in the healthcare field. Their application in pharmacokinetics is of potential interest due to...
2.
Ortea I, Rodriguez-Martinez L, Carrera M, Fafian-Labora J, Arufe M, Gonzalez-Barcia M, et al.
Biomed Pharmacother
. 2024 Nov;
181:117650.
PMID: 39504626
Cysteamine, an aminothiol, is the only available treatment for cystinosis, an incurable metabolic recessive disease characterized by detrimental symptoms at the renal, ocular, and muscular levels. Cystinosis is due to...
3.
Puente-Iglesias M, Cuartero-Martinez A, Tourino-Peralba R, Rodriguez-Ares M, Giraldez M, Yebra-Pimentel E, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337336
Ophthalmic tacrolimus compounded formulations are usually made from the commercial intravenous presentation, which contains ethanol as a solubilizer due to the low solubility of tacrolimus. The use of cyclodextrins is...
4.
Cuartero-Martinez A, Garcia-Otero X, Codesido J, Gomez-Lado N, Mateos J, Bravo S, et al.
Int J Pharm
. 2024 Jul;
662:124516.
PMID: 39067549
Uveitis is a group of inflammatory ocular pathologies. Endotoxin-Induced Uveitis (EIU) model represent a well-known model induced by administration of Lipopolysaccharide (LPS). The aim is to characterize two models of...
5.
Garcia-Quintanilla L, Almuina-Varela P, Rodriguez-Cid M, Gil-Martinez M, Abraldes M, Gomez-Ulla F, et al.
Pharmaceutics
. 2024 Jan;
16(1).
PMID: 38258115
Anti-vascular endothelial growth factor drugs keep being the main therapy for neovascular age-related macular degeneration (AMD). Possible predictive parameters (demographic, biochemical and/or inflammatory) could anticipate short-term treatment response with ranibizumab....
6.
Castro-Balado A, Cuartero-Martinez A, Pena-Verdeal H, Hermelo-Vidal G, Schmidt A, Montero B, et al.
Pharmaceutics
. 2023 Nov;
15(11).
PMID: 38004568
Background: Cystinosis is a rare genetic disorder characterized by the accumulation of cystine crystals in several tissues and organs causing, among others, severe eye symptoms. The high instability of cysteamine...
7.
Garcia-Quintanilla L, Almuina-Varela P, Maronas O, Gil-Rodriguez A, Rodriguez-Cid M, Gil-Martinez M, et al.
Invest Ophthalmol Vis Sci
. 2023 Oct;
64(13):34.
PMID: 37862026
Purpose: To determine whether genetic risk single nucleotide polymorphisms (SNPs) for age-related macular degeneration (AMD) influence short-term response to intravitreal ranibizumab treatment. Methods: Forty-four treatment-naive AMD patients were included in...
8.
Rodriguez-Martinez L, Castro-Balado A, Hermelo-Vidal G, Bandin-Vilar E, Varela-Rey I, Toja-Camba F, et al.
Pharmaceutics
. 2023 Aug;
15(8).
PMID: 37631313
Outpatient parenteral antimicrobial therapy (OPAT) with continuous infusion pumps is postulated as a very promising solution to treat complicated infections, such as endocarditis or osteomyelitis, that require patients to stay...
9.
Bandin-Vilar E, Garcia-Quintanilla L, Castro-Balado A, Zarra-Ferro I, Gonzalez-Barcia M, Campos-Toimil M, et al.
Clin Pharmacokinet
. 2023 Aug;
62(9):1331.
PMID: 37535241
No abstract available.
10.
Busto-Iglesias M, Rodriguez-Martinez L, Rodriguez-Fernandez C, Gonzalez-Lopez J, Gonzalez-Barcia M, de Domingo B, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986627
Biological drugs, especially those targeting anti-tumour necrosis factor α (TNFα) molecule, have revolutionized the treatment of patients with non-infectious uveitis (NIU), a sight-threatening condition characterized by ocular inflammation that can...